Stephen Bertram Soumerai, Sc.D.
This page shows the publications co-authored by Stephen Soumerai and Sebastian Schneeweiss.
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14; 346(11):822-9.
Prescription duration after drug copay changes in older people: methodological aspects. J Am Geriatr Soc. 2002 Mar; 50(3):521-5.
On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy. 2001 Feb; 55(2):97-109.
Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care. 2004 Jul; 42(7):653-60.
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003 Oct; 74(4):388-400.
Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clin Ther. 2003 Jan; 25(1):273-84.
Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002 Aug; 55(8):833-41.
Reference drug pricing. CMAJ. 2002 Jul 23; 167(2):126-7; author reply 127-8.
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002 Mar 19; 166(6):737-45.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.